Cetera Advisor Networks LLC Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG)


Share on StockTwits

Cetera Advisor Networks LLC acquired a new stake in 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,682 shares of the company’s stock, valued at approximately $238,000.

Several other hedge funds have also recently added to or reduced their stakes in TXG. LPL Financial LLC bought a new stake in shares of 10x Genomics in the third quarter valued at about $439,000. Allianz Asset Management GmbH lifted its position in shares of 10x Genomics by 938.0% during the third quarter. Allianz Asset Management GmbH now owns 44,013 shares of the company’s stock valued at $5,487,000 after buying an additional 39,773 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of 10x Genomics by 212.8% during the third quarter. Nuveen Asset Management LLC now owns 1,001,406 shares of the company’s stock valued at $124,856,000 after buying an additional 681,250 shares during the last quarter. State of Tennessee Treasury Department purchased a new position in shares of 10x Genomics in the 3rd quarter worth approximately $8,250,000. Finally, Point72 Asset Management L.P. raised its stake in shares of 10x Genomics by 136.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 97,077 shares of the company’s stock worth $12,104,000 after acquiring an additional 55,992 shares in the last quarter. Hedge funds and other institutional investors own 68.84% of the company’s stock.

In other news, Director John R. Stuelpnagel sold 7,500 shares of 10x Genomics stock in a transaction that occurred on Tuesday, January 19th. The shares were sold at an average price of $178.76, for a total transaction of $1,340,700.00. Following the completion of the transaction, the director now directly owns 479,591 shares of the company’s stock, valued at approximately $85,731,687.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Benjamin J. Hindson sold 41,666 shares of the stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $184.54, for a total transaction of $7,689,043.64. Following the sale, the insider now directly owns 78,302 shares in the company, valued at $14,449,851.08. The disclosure for this sale can be found here. Insiders sold 144,416 shares of company stock worth $25,731,264 in the last 90 days. Company insiders own 13.28% of the company’s stock.

Shares of NASDAQ TXG opened at $185.34 on Thursday. The company has a 50 day simple moving average of $174.12 and a two-hundred day simple moving average of $158.90. The stock has a market cap of $20.16 billion, a price-to-earnings ratio of -137.29 and a beta of 1.39. 10x Genomics, Inc. has a 12 month low of $59.36 and a 12 month high of $201.70.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Tuesday, February 16th. The company reported ($3.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($3.59). The business had revenue of $112.22 million for the quarter, compared to analyst estimates of $101.20 million. 10x Genomics had a negative net margin of 51.27% and a negative return on equity of 19.98%. Sell-side analysts forecast that 10x Genomics, Inc. will post -1.18 earnings per share for the current fiscal year.

TXG has been the topic of several analyst reports. Cowen lifted their price target on shares of 10x Genomics from $155.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, February 25th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on 10x Genomics from $165.00 to $195.00 in a research note on Wednesday, December 16th. William Blair began coverage on 10x Genomics in a report on Monday, March 22nd. They issued an “outperform” rating for the company. Citigroup upped their price objective on shares of 10x Genomics from $195.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, February 25th. Finally, Zacks Investment Research upgraded shares of 10x Genomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $183.70.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products.

Featured Article: Compound Interest

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.